看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 13.3x - 14.7x | 14.0x |
| Selected Fwd P/E Multiple | 9.1x - 10.1x | 9.6x |
| Fair Value | R140.76 - R155.58 | R148.17 |
| Upside | 18.0% - 30.5% | 24.2% |
| Benchmarks | - | Full Ticker |
| Adcock Ingram Holdings Limited | - | JSE:AIP |
| Viatris Inc. | - | WBAG:VTRS |
| Hikma Pharmaceuticals PLC | - | LSE:HIK |
| Perrigo Company plc | - | BOVESPA:P1RG34 |
| Teva Pharmaceutical Industries Limited | - | TASE:TEVA |
| Aspen Pharmacare Holdings Limited | - | JSE:APN |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| AIP | VTRS | HIK | P1RG34 | TEVA | APN | |||
| JSE:AIP | WBAG:VTRS | LSE:HIK | BOVESPA:P1RG34 | TASE:TEVA | JSE:APN | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 3.4% | NM- | -5.9% | NM- | NM- | 21.3% | ||
| 3Y CAGR | 7.4% | NM- | -5.2% | NM- | NM- | -2.8% | ||
| Latest Twelve Months | -13.1% | -1259.4% | 88.9% | -3552.3% | -193.2% | -8.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 9.0% | 0.0% | 13.4% | -2.2% | -10.5% | 13.1% | ||
| Prior Fiscal Year | 9.8% | 0.4% | 6.6% | -0.1% | -3.5% | 12.8% | ||
| Latest Fiscal Year | 8.4% | -4.3% | 11.5% | -3.7% | -9.9% | 9.9% | ||
| Latest Twelve Months | 7.9% | -4.3% | 11.5% | -3.7% | -9.9% | 9.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 5.9x | 5.2x | 8.9x | 8.9x | 7.6x | 7.6x | ||
| Price / LTM Sales | 0.7x | 0.7x | 1.9x | 0.8x | 1.1x | 1.2x | ||
| LTM P/E Ratio | 9.4x | -16.2x | 16.4x | -21.4x | -11.3x | 11.8x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -21.4x | -11.3x | 16.4x | |||||
| Historical LTM P/E Ratio | 10.0x | 18.7x | 22.4x | |||||
| Selected P/E Multiple | 13.3x | 14.0x | 14.7x | |||||
| (x) LTM Net Income | 4,478 | 4,478 | 4,478 | |||||
| (=) Equity Value | 59,554 | 62,689 | 65,823 | |||||
| (/) Shares Outstanding | 444.2 | 444.2 | 444.2 | |||||
| Implied Value Range | 134.07 | 141.12 | 148.18 | |||||
| FX Rate: ZAR/ZAR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 134.07 | 141.12 | 148.18 | 119.26 | ||||
| Upside / (Downside) | 12.4% | 18.3% | 24.2% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | AIP | VTRS | HIK | P1RG34 | TEVA | APN | |
| Value of Common Equity | 7,162 | 10,401 | 5,911 | 3,495 | 18,509 | 52,977 | |
| (/) Shares Outstanding | 146.8 | 1,193.7 | 220.4 | 136.5 | 1,147.0 | 444.2 | |
| Implied Stock Price | 48.80 | 8.71 | 26.81 | 25.61 | 16.14 | 119.26 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.13 | 1.34 | 0.17 | 0.28 | 1.00 | |
| Implied Stock Price (Trading Cur) | 48.80 | 7.68 | 20.06 | 146.55 | 58.15 | 119.26 | |
| Trading Currency | ZAR | EUR | GBP | BRL | ILS | ZAR | |
| FX Rate to Reporting Currency | 1.00 | 1.13 | 1.34 | 0.17 | 0.28 | 1.00 | |